Szpital Uniwersytecki nr 2 im. dr Jana Biziela
Welcome,         Profile    Billing    Logout  
 5 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vannucchi, Alessandro
AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT06401356: An Extension Study for Patients Previously Enrolled in Studies with Pelabresib

Recruiting
3
50
Europe, US
Pelabresib, CPI-0610
Constellation Pharmaceuticals
Hematologic Malignancy, Solid Tumor, Advanced Malignancies
06/29
06/29
ACCESS-EXT, NCT05744921 / 2021-004931-10: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.

Recruiting
3
202
Europe, Canada, Japan, RoW
Pozelimab, REGN3918, Cemdisiran, ALN-CC5
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
02/29
02/29
ENABLE, NCT04763928 / 2020-006114-20: Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

Active, not recruiting
2
101
Europe
Venetoclax+Decitabine
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Gimema Franco Mandelli Onlus, AbbVie Srl
Acute Myeloid Leukemia
10/24
04/26
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19

Recruiting
N/A
552
Europe, US, RoW
Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net
Myeloproliferative Neoplasm, COVID
02/22
08/22
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

Recruiting
N/A
319
Europe
Ropeginterferon alfa-2b, Besremi
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
09/26
12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Recruiting
N/A
617
Europe, RoW
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline
Myelofibrosis
12/24
12/28
Lucchesi, Alessandro
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Hourglass Jul 2024 - Dec 2024 : Data from trial for warm autoimmune hemolytic anemia
Active, not recruiting
2
22
Europe, US, RoW
rilzabrutinib, PRN1008/SAR444671
Sanofi, Sanofi Aventis Recherche et Developpement
Warm Autoimmune Hemolytic Anemia (wAIHA)
05/24
05/25
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

Recruiting
N/A
2000
Europe
clinical data and sample collection
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna
Haematologic Disease, Haematological Malignancy
02/25
02/25
Czyż, Jarosław
POTAMI-61, NCT06397313: RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Recruiting
2
230
Europe
RVU120, SEL120, Ruxolitinib, RUX
Ryvu Therapeutics SA
Myelofibrosis
06/26
10/27

Download Options